Therapeutic Solutions International Expands Adoptive Immunotherapy Portfolio by Incorporation of "Universal Cancer Antigen" into StemVacs Dendritic Cell Platform
OCEANSIDE, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire --Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today initiation of efforts to combine its existing CTCFL "universal cancer antigen", labeled as BRS-001, with its clinical stage StemVacs Dendritic Cell Platform.
The Company previously filed a patent on technologies covering novel means of stimulating the immune system to kill cancer using naturally made nanoparticles termed "exosomes"1. The patent whose Mexican rights are licensed to the Pan Am Cancer Treatment Centers covers the production and composition of matter of agents aimed at immunologically eradicating cancer stem cells. In contrast to previous exosome-based cancer therapeutic approaches, the strategy disclosed in the patent involves focusing the immune system to attack the CTCFL protein, which is selectively found on cancer stem cells2.
"The CTCFL or BORIS protein represents a unique onco-target in the fight against cancer since it is only found on cancer cells and not healthy tissues. Our strategy possesses the possibility of inducing an immune response that would strike cancer at its very roots, the cancer stem cells," said Timothy Dixon, President and CEO of Therapeutic Solutions International.
"The recently approved Right to Try Law allows for accelerated clinical development of therapeutics that possess Phase I data. We plan to leverage this and other programs to take our scientific discoveries from the bench to the patient's bedside," said Dr. James Veltmeyer, Member of the Company's Scientific Advisory Board.
About Therapeutic Solutions International, Inc. Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is www.therapeuticsolutionsint.com and e-commerce at www.youcanordernow.com.
www.otcmarkets....TSOI/news/story?e&id=1...
OCEANSIDE, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire --Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today initiation of efforts to combine its existing CTCFL "universal cancer antigen", labeled as BRS-001, with its clinical stage StemVacs Dendritic Cell Platform.
The Company previously filed a patent on technologies covering novel means of stimulating the immune system to kill cancer using naturally made nanoparticles termed "exosomes"1. The patent whose Mexican rights are licensed to the Pan Am Cancer Treatment Centers covers the production and composition of matter of agents aimed at immunologically eradicating cancer stem cells. In contrast to previous exosome-based cancer therapeutic approaches, the strategy disclosed in the patent involves focusing the immune system to attack the CTCFL protein, which is selectively found on cancer stem cells2.
"The CTCFL or BORIS protein represents a unique onco-target in the fight against cancer since it is only found on cancer cells and not healthy tissues. Our strategy possesses the possibility of inducing an immune response that would strike cancer at its very roots, the cancer stem cells," said Timothy Dixon, President and CEO of Therapeutic Solutions International.
"The recently approved Right to Try Law allows for accelerated clinical development of therapeutics that possess Phase I data. We plan to leverage this and other programs to take our scientific discoveries from the bench to the patient's bedside," said Dr. James Veltmeyer, Member of the Company's Scientific Advisory Board.
About Therapeutic Solutions International, Inc. Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is www.therapeuticsolutionsint.com and e-commerce at www.youcanordernow.com.
www.otcmarkets....TSOI/news/story?e&id=1...